Congenital Adrenal Hyperplasia Market
Congenital Adrenal Hyperplasia (CAH)

Congenital Adrenal Hyperplasia


Congenital adrenal hyperplasia (CAH) is a group of rare inherited autosomal recessive disorders characterized by a deficiency of one of the enzymes needed to make specific hormones. CAH affects the adrenal glands located at the top of each kidney.

The most common cause of CAH is the absence of the enzyme 21-hydroxylase. Different mutations in the gene are responsible for 21-hydroxylase, which results in different levels of the enzyme, producing a spectrum of effects.


Congenital Adrenal Hyperplasia Epidemiology Segmentation in the 7MM


  • Total Prevalent Cases of Congenital Adrenal Hyperplasia
  • Total Diagnosed Cases of Congenital Adrenal Hyperplasia
  • Diagnosed Prevalent Cases of Classic and Nonclassic Congenital Adrenal Hyperplasia

 

Congenital Adrenal Hyperplasia Epidemiological Insights Observed in the 7MM (2021)


  • The total incident cases of Congenital Adrenal Hyperplasia observed in the 7MM were observed to be 73K in the year 2021


Congenital Adrenal Hyperplasia Market Insight

The market size of Congenital Adrenal Hyperplasia in the 7MM was found to be approximately USD 21 Million in 2021.  

Congenital Adrenal Hyperplasia Emerging Drugs


The emerging drugs in the Congenital Adrenal Hyperplasia market are

  • NBI-74788
  • Tildacerfont
  • BBP-631, and others


Congenital Adrenal Hyperplasia Key Players 


The key players working in the Congenital Adrenal Hyperplasia market are


  • Adrenas Therapeutics Inc
  • Spruce Biosciences
  • Neurocrine Biosciences, and others

Congenital Adrenal Hyperplasia Market Insight

Download Infographic